<- Go Home
Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Market Cap
$15.2B
Volume
541.3K
Cash and Equivalents
$996.7M
EBITDA
$1.8B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.7B
Profit Margin
61.57%
52 Week High
$300.00
52 Week Low
$143.40
Dividend
N/A
Price / Book Value
1.43
Price / Earnings
13.67
Price / Tangible Book Value
3.58
Enterprise Value
$13.4B
Enterprise Value / EBITDA
7.47
Operating Income
$1.2B
Return on Equity
11.17%
Return on Assets
5.49
Cash and Short Term Investments
$1.9B
Debt
$114.3M
Equity
$10.7B
Revenue
$6.1B
Unlevered FCF
-$35.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium